Loading organizations...
MS Ventures operates as a specialized division of Manhattan Strategies, providing comprehensive advisory services aimed at preparing high-potential companies for capital acquisition. The firm focuses on developing compelling narratives, refining pitch decks, and constructing robust financial models, all critical components for businesses seeking investment. Their approach integrates strategic communication, visual storytelling, and brand development to articulate a venture's value proposition effectively to potential investors.
The entity was founded by Max Morgan, who also serves as the managing principal of Manhattan Strategies. Established with the insight that visual and strategic communication significantly enhances a company's ability to attract capital and drive action, the venture communications practice has been active since 2019. Morgan's pedigree in strategic communications underpins the firm’s methodology, emphasizing clarity and impact in investor relations.
MS Ventures primarily serves founders, startups, and growth-stage companies across various industries, guiding them through the intricate process of securing funding. The firm’s vision is to empower disruptors by transforming their innovative ideas into investor-ready propositions, thereby facilitating the flow of capital to ventures poised to shape future markets and technologies. They aim to be a crucial partner in accelerating the growth of ambitious enterprises.
MS Ventures has 4 tracked investments across 4 companies. The latest tracked deal is $4.0M Seed in Inthera Bioscience in December 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2015 | Inthera Bioscience | $4.0M Seed | MS Ventures | Aglaia BioMedical Ventures, Keno Gutierrez, Forbion, EVA%20Basel, Novo Seeds |
| Nov 1, 2015 | ObsEva | $59.0M Series B | — | Acorn Bioventures, NEW Enterprise Associates, Rivervest, Sofinnova Investments, HBM Healthcare Investments, Novo Ventures, OrbiMed, Rock Springs Capital, Sofinnova Partners |
| Jul 1, 2015 | Translate Bio | $64.0M Series B | Baupost Group, Joshua Resnick | Atlas Venture, Dcvc (data Collective), Brookside Capital, Leerink Partners, Monsanto, Omega Funds, Partners Innovation Fund, Rock Springs Capital, SR ONE |
| Oct 1, 2013 | F-Star Therapeutics | $9.0M Star Therapeutics - Series A | — | Atlas Venture, INKEF Capital, Aescap Venture, MP Healthcare Venture Management, SR ONE, TVM Capital |